| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2143552 | Lung Cancer | 2008 | 4 Pages |
Abstract
SummaryThe role of second line treatment in malignant pleural mesothelioma (MPM) is currently undefined. We present four cases of patients who had durable responses from pemetrexed-based chemotherapy who were retreated with a similar regimen upon progression of their mesothelioma. This case series explores the possible role of retreatment with pemetrexed-based chemotherapy as a second line therapeutic option in MPM.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Albiruni Ryan Abdul Razak, Katy J. Chatten, Andrew N. Hughes,